Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - Update of clinical and translational data from the ongoing MANIFEST trial
    Meeting Abstract

    Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Vannucchi, A.; Verstovsek, S.; Harrison, C. N.; Bose, P.; Schiller, G. J.; Rampal, R.; Drummond, M. W.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The High Mobility Group A1 chromatin regulator drives immune evasion during MPN progression by repressing genes involved in antigen presentation and immune attack
    Meeting Abstract

    Kim, J.; Kim, J. H.; Cope, L.; Li, L.; Rampal, R.; Koche, R.; Williams, D. M.; Spivak, J. L.; Moliterno, A. R.; Resar, L.
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in patients with relapsed/refractory chronic lymphocytic leukemia: Preliminary results from the EPCORE CLL-1 trial
    Meeting Abstract

    Kater, A. P.; Christensen, J. H.; Bentzen, H. H.; Niemann, C. U.; Hutchings, M.; Chen, J.; Rios, M.; Palenski, T.; Li, T.; Mato, A. R.
    Blood (2021)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic- phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Meeting Abstract

    Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J. F.; Cortes, J. E.; Chuah, C.; DeAngelo, D.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Risks for hospitalization and death among patients with blood disorders from the ASH RC COVID-19 Registry for Hematology
    Meeting Abstract

    Hicks, L. K.; Redd, R. A.; Anderson, K. C.; Desai, P.; Dolan, B.; Goldberg, A. D.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Sehn, L. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I and expansion study of eprenetapopt (APR-246) in combination with venetoclax (VEN) and azacitidine (AZA) in TP53-mutant acute myeloid leukemia (AML)
    Meeting Abstract

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P.; Altman, J. K.; Cherry, M.; Tomlinson, B.; Chandhok, N.; Zhang, H.; Rastgoo, N.; Benbatoul, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia
    Meeting Abstract

    Grenet, J.; Jain, A. G.; Burkart, M.; Waksal, J.; Famulare, C.; Numan, Y.; Stahl, M.; Mckinnell, Z.; Ball, B.; Ma, X.; more...
    Blood (2021)

    Fulltext@MSK | Save